CYCLOTEC™ Brings Canada Closer to Solving Medical Isotope Shortage

advanced-cyclotron

Richmond, BC, October 25, 2012 – Advanced Cyclotron Systems Inc. (“ACSI”) of Richmond, British Columbia, announces a new product for the medical imaging sector. This new product, called CYCLOTEC™, is the medical isotope technetium-99m (“Tc-99m”) that is produced in cyclotrons using ACSI’s exclusive target irradiation hardware system.

Researchers at the University of Alberta’s (“U of A”) Alberta Health Services have successfully used the product to generate medical images from cancer patients. This achievement was the result of an ongoing collaboration between U of A in Edmonton, the Centre Hospitalier Universitaire de Sherbrooke (“CHUS”) in Quebec, and ACSI. The initiative was supported by the Government of Canada which in 2011, through the Non-reactor-based Isotope Supply Contribution Program (NISP), contributed $11 million to build two new CYCLOTEC™ production facilities in Sherbrooke and Edmonton. The preliminary, successful use of cyclotron-produced Tc-99m for scanning patients was led by Dr. Sandy McEwan of U of A and Dr. Eric Turcotte of CHUS.

Medical isotopes are used in 50 million nuclear medicine imaging procedures globally every year. The unreliability of the aging nuclear reactors that produce medical isotopes has resulted in the need to seek alternatives to existing methods of production. The successful results of the research done by U of A, CHUS, and ACSI demonstrate that CYCLOTEC™ is a viable alternative to Tc-99m produced by nuclear reactors. The production of CYCLOTEC™ with a cyclotron is safer and more reliable when compared to Tc-99m that is produced in a nuclear reactor. Nuclear reactors require weapons-grade uranium to produce molybdenum-99, which decays into Tc-99m for use in patients. This process creates long-lived radioactive nuclear waste, which must be disposed of in special containers. The process of using a cyclotron offers a “greener” production process. CYCLOTEC™ can also be produced at a faster rate (daily with an ACSI cyclotron, compared to weekly with that of a nuclear reactor), and it offers the ability to be produced on site.

“With further testing and development underway, the first successful human scans performed in Edmonton have demonstrated that CYCLOTEC™ can be a safe and effective replacement for reactor-generated isotopes,” says Richard Eppich, ACSI’s President and CEO. “The successful demonstration of CYCLOTEC™ in patients also supports ACSI and its partners’ proposal to establish a Canada-wide network of cyclotron sites for producing and supplying CYCLOTEC™ and other isotopes used in medical imaging.” ACSI is in the process of registering CYCLOTEC™ as a trade-mark in various jurisdictions and ACSI is currently seeking regulatory approval from Health Canada for its use.

About ACSI: ACSI is the leading manufacturer of high-output commercial cyclotrons for the international nuclear medicine community. Cyclotrons are particle accelerators used to produce isotopes. Its cyclotrons are used for the commercial production and distribution of PET and SPECT isotopes by internationally recognized companies and leading research facilities.

For More Information Please Contact:

Richard Eppich, President & CEO Advanced Cyclotron Systems Inc. Phone: 604-276-1493 or 1-877-270-1493 Info@advancedcyclotron.com Markus Pauli, COO Advanced Cyclotron Systems Inc. Phone: 604-276-1493 or 1-877-270-1493 Info@advancedcyclotron.com

Share This Post

To bookmark this page, press the Ctrl (PCs) or Command (Macs) and D keys on your keyboard.

Email to a Friend:

Return to: Main Blog